FAP CAR-T cell therapy

FAP CAR-T cell therapy is an adoptive cell therapy that involves genetically engineering a patient's T cells to express a Chimeric Antigen Receptor (CAR) designed to specifically recognize Fibroblast Activation Protein (FAP). FAP is a cell surface serine protease that is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) of over 90% of epithelial cancers, including colorectal, pancreatic, liver, and breast cancers. By targeting FAP-positive CAFs, these engineered T cells aim to disrupt the immunosuppressive TME, reduce tumor growth, and potentially enhance the efficacy of other immunotherapies. This therapeutic strategy is being investigated for solid tumors, where conventional CAR-T cell therapies have faced challenges due to the complex and restrictive TME. Preclinical studies have demonstrated significant anti-tumor effects in various solid tumor models, and clinical trials are underway to evaluate the safety and efficacy of FAP-targeted CAR-T cells in human patients.

Other names

FAP-targeted CAR-T cellsanti-FAP CAR-T cells